linjc16/ctgov huggingface dataset:
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Study Overview
=================
Brief Summary
-----------------
This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

Detailed Description
-----------------
OBJECTIVES: I. Collect biological specimens, including associated demographic and clinical data, from patients with Ewing sarcoma. II. Provide a repository for long-term storage of Ewing sarcoma-related biological materials. III. Make collected specimens available to qualified researchers to understand the biology of Ewing sarcoma and correlate these results with demographic and clinical data. OUTLINE: This is a multicenter study. Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.

Official Title
-----------------
A COG Study for Collecting and Banking Ewing Sarcoma Specimens

Conditions
-----------------
Askin Tumor, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Intervention / Treatment
-----------------
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Ewing sarcoma, including peripheral primitive neuroectodermal tumor and Askin tumor Newly diagnosed or recurrent disease

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (biomarker sampling)<br>Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually. | Other: Laboratory Biomarker Analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Banking of biological specimens, including associated demographic and clinical data |  | Not Provided |
USDA Behavior, Motivation & Nutrition Study

Study Overview
=================
Brief Summary
-----------------
This study will be a cross-sectional study. The primary aim of this study is to compare the relationship between neurological function, metabolic measures and health-related behaviors between normal weight and overweight/obese perimenopausal women.

Detailed Description
-----------------
To examine physiological and behavioral factors that may help determine health in perimenopausal middle age women. Neuroendocrine function will be measured by broad assessment of hypothalamic-pituitary-adrenal (HPA) activity. We will also assess metabolic profiles and behavioral and emotional function. We plan to determine correlations between these measures and nutritional state. Other measures may include insulin, glucose, leptin, IGF-1, triglycerides, free fatty acids, and ghrelin and eating attitudes and physical reactivity.

Official Title
-----------------
Examination of Metabolic Determinants of Behavior and Motivation in Obesity: Implication to the Development of New Strategies for Achieving Body Weight Health

Conditions
-----------------
Body Weight

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body Mass index 18-39.9 kg/m2 Peri-menopausal status by self-report Exclusion Criteria: Pregnant Plan to become pregnant Breastfeeding in the last 6 months Multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease Menopause confirmed Unable to refrain from smoking for five hours (self-report) Unable to refrain from consuming alcohol for two days (self-report) Weight change > 10 lbs in the preceding 6 months Chronic corticosteroid use Oral corticosteroids used more than twice in the last 12 months Hormonal contraceptives Antipsychotic, anti-anxiety and anti-depressant medications Beta adrenergic blockers Sibutramine, orlistat, phentermine, phendimetrazine, topiramate, zonisamide Immunosuppressants Amphetamines and other stimulants Severe food allergies or intolerances to foods Insulin Dependent Diabetes Mellitus

Ages Eligible for Study
-----------------
Minimum Age: 42 Years
Maximum Age: 52 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between metabolic measures and health-related behaviors in normal weight and overweight/obese perimenopausal women. |  | 3 months |
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Study Overview
=================
Brief Summary
-----------------
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Detailed Description
-----------------
Conducted in Europe

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Botulinum neurotoxin type A, free of complexing proteins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy females, 18 to 65 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Botulinum neurotoxin type A, free of complexing proteins|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of area |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
No condition, healthy volunteers
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Levetiracetam 750 mg Tablets under fasted conditions

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

Conditions
-----------------
Seizures

Intervention / Treatment
-----------------
* Drug: Levetiracetam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Levetiracetam or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Levetiracetam|750 mg tablet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalance based on Cmax |  | 10 days |
Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of DNA from patients receiving gemtuzumab ozogamicin may help doctors learn more about the effects of gemtuzumab ozogamicin on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research study is studying biomarkers in DNA samples from younger patients with newly diagnosed with acute myeloid leukemia receiving gemtuzumab ozogamicin.

Detailed Description
-----------------
OBJECTIVES: To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on COG-AAML03P1. To determine the association between these polymorphisms and clinical response of patients treated with this regimen. OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based sequencing.

Official Title
-----------------
Pharmacogenetics of Mylotarg

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: DNA analysis
* Genetic: polymerase chain reaction
* Other: laboratory biomarker analysis
* Other: pharmacological study


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Newly diagnosed acute myeloid leukemia Treated with gemtuzumab ozogamicin on COG-AAML03P1 Genomic DNA samples available PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA analysis|nan|
|Genetic: polymerase chain reaction|nan|
|Other: laboratory biomarker analysis|nan|
|Other: pharmacological study|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
untreated childhood acute myeloid leukemia and other myeloid malignancies
Prophylactic Post-Cesarean Incisional Negative-pressure Wound Therapy in Morbidly Obese Patients

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness of negative-pressure wound therapy in decreasing wound complications in morbidly obese patients (BMI greater than of equal to 40) at Albany Medical Center Hospital. Retrospective data will be collected regarding morbidly obese patients who have undergone cesarean section and patients will be recruited to have the intervention (negative-pressure wound therapy) applied and outcomes will be evaluated.

Conditions
-----------------
Negative-pressure Wound Therapy, Morbid Obesity, Cesarean Section, Wound Infection

Intervention / Treatment
-----------------
* Device: Negative-pressure wound therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing cesarean section at Albany Medical Center Hospital Current BMI greater than or equal to 40 Exclusion Criteria: Current BMI less than 40 current skin or soft tissue infection skin or soft tissue disorder allergy to silver

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Retrospective<br>Standard dry sterile dressing | |
| Experimental: Prospective<br>Negative-pressure wound therapy | Device: Negative-pressure wound therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound complication |  | 3 months |
Ocular Penetration of Topical Tacrolimus Eye Drops

Study Overview
=================
Brief Summary
-----------------
Investigators aim to evaluate the ocular penetration of topical tacrolimus 0.03% eye drops. Topical tacrolimus 0.03% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.

Conditions
-----------------
Ocular Penetration of Topical Tacrolimus

Intervention / Treatment
-----------------
* Drug: Tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any age or gender Patients scheduled for routine cataract surgery Clear healthy cornea Exclusion Criteria: Corneal pathology Ocular surface disease Intraocular inflammation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Topical tacrolimus<br>Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus. | Drug: Tacrolimus<br>* Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of the concentration of tacrolimus ( nanograms/milliliter) in the anterior chamber following ocular topical application. |  | From date of obtaining the aqueous samples until getting the laboratory results of concentration of topical tacrolimus in the aqueous humor up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tacrolimus, Ocular penetration, Topical
Evaluation of NICOM (Bioreactance) for the Non-invasive Determination of Cardiac Output

Study Overview
=================
Brief Summary
-----------------
Cardiac output (CO) is an important parameter in the diagnosis and therapy of cardiac diseases. The current standard methods for the determination of CO, however, are either invasive (e.g. right heart catheterization) or technically expendable and expensive (magnetic resonance tomography, MRT). Therefore, the aim of the study at hand was to evaluate NICOM (bioreactance) as a new method for determinion of CO and to compare this new technique to MRT.

Conditions
-----------------
Cardiac Disease

Intervention / Treatment
-----------------
* Device: NICOM cardiac output measurement
* Device: Cardiac MRT cardiac output measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: indication for cardiac magnetic resonance imaging Exclusion Criteria: pace maker patient unwilling to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: NICOM cardiac output measurement|nan|
|Device: Cardiac MRT cardiac output measurement|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| agreement of NICOM and MRT cardiac output measurements |  | at time of inclusion | 
| precision of NICOM cardiac output measurements |  | at time of inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Accuracy of NICOM, precision of NICOM
Alcohol and Women : Screening in General

Study Overview
=================
Brief Summary
-----------------
The alcohol consumption of adults has been decreasing in France since the sixties. When focusing on the particular case of women, this trend goes on the opposite direction. In addition, the impact of drinking alcohol involves an increased severity in women in comparison to men. Furthermore, women consult less often doctors about their alcohol problem due to stigmatisation. Finally, as alcohol consumption is a major public health issue (second preventable cause of death), the aim of this study is to propose an earlier screening of women with alcohol use disorders (AUD) in general medicine.

Detailed Description
-----------------
To improve the screening of women with AUD in general médicine, from their perceptions and experiences, and to create a screening tool to general practitioners. The chosen method is a qualtitative study through semi-structured interview with women with AUD. A qualitative assessment of these individual interviews could show various topics.

Official Title
-----------------
Alcohol and Women : Screening in General Medicine.

Conditions
-----------------
Alcoholism

Intervention / Treatment
-----------------
* Other: interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - over 18 years old alcoholic women, with one or several addiction, from all social class. Exclusion criteria: - not being able to answer the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: interviews|interviews (human and social sciences)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of women's opinion on an alcoholism screening by general practitioners. | Assessment of women's opinion on an alcoholism screening by general practitioners : Qualitative study based on semi-structured interview with women with AUD. | 1 year | 
| Creation of a screening tool dedicated to general practitioners | Creation of a screening tool dedicated to general practitioners : Built of a screening tool based both on litterature review about alcohol & women and a qualitative study on women's opinion. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
women reporting alcohol abuse and/or dependence, women recruted during hospitalisation and/or consultation, Alcohol
Teleconsultation in Ambulatory Care in France

Study Overview
=================
Brief Summary
-----------------
Teleconsultation is a telemedicine medical act carried out remotely via information and communication technologies. This medical procedure has been legal in France since 2010 and reimbursed by the National Health Insurance under certain conditions since 2018. In 2020, following the COVID-19 epidemic, the lockdowns and the extension of the scope of financial coverage, 17 million teleconsultations have been reimbursed. To date, few scientific studies have been published in France to precisely describe the use of the service giving access to outpatient teleconsultation, in particular since the major increase in activity linked to the COVID-19 epidemic. The objective is to describe the use of the service giving access to outpatient teleconsultation carried out in France by teleconsultation companies and compare the use of the teleconsultation service according to the medical density of the territory.

Official Title
-----------------
Observational Study of the Use of the Service Giving Access to Teleconsultation in France by Telemedicine Companies

Conditions
-----------------
Telehealth, Telemedicine, Teleconsultation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who used the teleconsultation access service with one of the telemedicine companies member of the LET participating in the study Patient residing in France according to the written information (address and or postal code) given at registration to the telemedicine company Teleconsultation service used between August 1, 2021 and November 30, 2021 Teleconsultation service used in the context of outpatient care (hospitals excluded) Teleconsultation service used for a teleconsultation with a doctor registered with the Medical Doctors Council in France
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients without a treating doctor |  | Through the study completion at the time of the teleconsultation, average 1 day |